Cargando…

Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation

BACKGROUND: Recombinant human growth hormone (rhGH) is frequently used for treatment of short stature in children with chronic kidney disease (CKD) prior to kidney transplantation (KT). To what extent this influences growth and transplant function after KT is yet unknown. METHODS: Post-transplant gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagodzinski, Celina, Mueller, Sophia, Kluck, Rika, Froede, Kerstin, Pavičić, Leo, Gellermann, Jutta, Mueller, Dominik, Querfeld, Uwe, Haffner, Dieter, Zivicnjak, Miroslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960657/
https://www.ncbi.nlm.nih.gov/pubmed/34542703
http://dx.doi.org/10.1007/s00467-021-05222-5
_version_ 1784677424282206208
author Jagodzinski, Celina
Mueller, Sophia
Kluck, Rika
Froede, Kerstin
Pavičić, Leo
Gellermann, Jutta
Mueller, Dominik
Querfeld, Uwe
Haffner, Dieter
Zivicnjak, Miroslav
author_facet Jagodzinski, Celina
Mueller, Sophia
Kluck, Rika
Froede, Kerstin
Pavičić, Leo
Gellermann, Jutta
Mueller, Dominik
Querfeld, Uwe
Haffner, Dieter
Zivicnjak, Miroslav
author_sort Jagodzinski, Celina
collection PubMed
description BACKGROUND: Recombinant human growth hormone (rhGH) is frequently used for treatment of short stature in children with chronic kidney disease (CKD) prior to kidney transplantation (KT). To what extent this influences growth and transplant function after KT is yet unknown. METHODS: Post-transplant growth (height, sitting height, leg length) and clinical parameters of 146 CKD patients undergoing KT before the age of 8 years, from two German pediatric nephrology centers, were prospectively investigated with a mean follow-up of 5.56 years. Outcome in patients with (rhGH group) and without (non-prior rhGH group) prior rhGH treatment was assessed by the use of linear mixed-effects models. RESULTS: Patients in the rhGH group spent longer time on dialysis and less frequently underwent living related KT compared to the non-prior rhGH group but showed similar height z-scores at the time of KT. After KT, steroid exposure was lower and increments in anthropometric z-scores were significantly higher in the rhGH group compared to those in the non-prior rhGH group, although 18% of patients in the latter group were started on rhGH after KT. Non-prior rhGH treatment was associated with a faster decline in transplant function, lower hemoglobin, and higher C-reactive protein levels (CRP). After adjustment for these confounders, growth outcome did statistically differ for sitting height z-scores only. CONCLUSIONS: Treatment with rhGH prior to KT was associated with superior growth outcome in prepubertal kidney transplant recipients, which was related to better transplant function, lower CRP, less anemia, lower steroid exposure, and earlier maturation after KT. GRAPHICAL ABSTRACT: A higher resolution version of the Graphical abstract is available as Supplementary information [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00467-021-05222-5.
format Online
Article
Text
id pubmed-8960657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89606572022-04-07 Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation Jagodzinski, Celina Mueller, Sophia Kluck, Rika Froede, Kerstin Pavičić, Leo Gellermann, Jutta Mueller, Dominik Querfeld, Uwe Haffner, Dieter Zivicnjak, Miroslav Pediatr Nephrol Original Article BACKGROUND: Recombinant human growth hormone (rhGH) is frequently used for treatment of short stature in children with chronic kidney disease (CKD) prior to kidney transplantation (KT). To what extent this influences growth and transplant function after KT is yet unknown. METHODS: Post-transplant growth (height, sitting height, leg length) and clinical parameters of 146 CKD patients undergoing KT before the age of 8 years, from two German pediatric nephrology centers, were prospectively investigated with a mean follow-up of 5.56 years. Outcome in patients with (rhGH group) and without (non-prior rhGH group) prior rhGH treatment was assessed by the use of linear mixed-effects models. RESULTS: Patients in the rhGH group spent longer time on dialysis and less frequently underwent living related KT compared to the non-prior rhGH group but showed similar height z-scores at the time of KT. After KT, steroid exposure was lower and increments in anthropometric z-scores were significantly higher in the rhGH group compared to those in the non-prior rhGH group, although 18% of patients in the latter group were started on rhGH after KT. Non-prior rhGH treatment was associated with a faster decline in transplant function, lower hemoglobin, and higher C-reactive protein levels (CRP). After adjustment for these confounders, growth outcome did statistically differ for sitting height z-scores only. CONCLUSIONS: Treatment with rhGH prior to KT was associated with superior growth outcome in prepubertal kidney transplant recipients, which was related to better transplant function, lower CRP, less anemia, lower steroid exposure, and earlier maturation after KT. GRAPHICAL ABSTRACT: A higher resolution version of the Graphical abstract is available as Supplementary information [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00467-021-05222-5. Springer Berlin Heidelberg 2021-09-20 2022 /pmc/articles/PMC8960657/ /pubmed/34542703 http://dx.doi.org/10.1007/s00467-021-05222-5 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Jagodzinski, Celina
Mueller, Sophia
Kluck, Rika
Froede, Kerstin
Pavičić, Leo
Gellermann, Jutta
Mueller, Dominik
Querfeld, Uwe
Haffner, Dieter
Zivicnjak, Miroslav
Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
title Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
title_full Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
title_fullStr Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
title_full_unstemmed Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
title_short Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
title_sort growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960657/
https://www.ncbi.nlm.nih.gov/pubmed/34542703
http://dx.doi.org/10.1007/s00467-021-05222-5
work_keys_str_mv AT jagodzinskicelina growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT muellersophia growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT kluckrika growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT froedekerstin growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT pavicicleo growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT gellermannjutta growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT muellerdominik growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT querfelduwe growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT haffnerdieter growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation
AT zivicnjakmiroslav growthhormonetreatmentinthepretransplantperiodisassociatedwithsuperioroutcomeafterpediatrickidneytransplantation